Hopp til hovedinnhold

C10 Lipidmodifiserende legemidler

Sist oppdatert: Sist revidert:
Sist revidert av:


  • Legemiddelkapittelet bygger på informasjon fra Felleskatalogen, Norsk Legemiddelhåndbok og diverse farmakologiske oppslagsverk
  1. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010 Apr;35(2):139-51. PMID: 20456733. PubMed  
  2. Silverman MG, Ference BA, Im K,et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016 Sep 27;316(12):1289-97. PMID: 27673306. PubMed  
  3. Chopra V, Wesorick DH, Sussman JB, et al. Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: A systematic review and meta-analysis. Arch Surg 2012; 147: 181-9. PubMed  
  4. Ying H, Wang J, Shen Z, Wang M, Zhou B. Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2020 Aug 8. Epub ahead of print. PMID: 32770521. PubMed  
  5. Zhang X, Wen J, Zhang Z. Statins use and risk of dementia: A dose-response meta analysis. Medicine (Baltimore). 2018 Jul;97(30):e11304. PMID: 30045255.
  6. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;3(2):CD003177. Published 2020 Feb 29. doi:10.1002/14651858.CD003177.pub5 DOI  
  7. Lombardi M, Chiabrando JG, Vescovo GM, et al. Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis. Curr Atheroscler Rep. 2020 Jul 16;22(9):45. PMID: 32671519. PubMed  
  8. Hoang T, Kim J. Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants. Nutrients. 2020 Jul 25;12(8):E2218. PMID: 32722395. PubMed  
  9. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97. Epub 2015 Jun 3. PMID: 26039521. PubMed  
  10. Sabatine MS, Giugliano RP, Keech AC, et. al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. Epub 2017 Mar 17. PMID: 28304224. PubMed  
  11. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J 2006; 151: 273-81. PubMed  
  12. Adams SP, Sekhon SS, Wright JM. Lipid-lowering efficacy of rosuvastatin. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No.: CD010254. Cochrane (DOI)  
  13. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol 2021 Sep 21; 78:1210. PMID: 34531021 PubMed  
  14. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; doi:10.1016/S0140-6736(10)61272-X. DOI  
  15. Tiniakou E. Statin-Associated Autoimmune Myopathy: Current Perspectives. Ther Clin Risk Manag. 2020 May 27;16:483-492. PMID: 32581543. PubMed  
  16. Mohaupt MG, Karas RH, Babiychuk EB, et al. Association between sratin-associated myopathy and skeletal muscle damage. CMAJ 2009; 181: E11-8. Canadian Medical Association Journal  
  17. Mansi I, et al. Statins and musculoskeletal conditions, arthropaties, and iinjuries. JAMA Intern Med 2013. doi:10.1001/jamainternmed.2013.6184 DOI  
  18. Dormuth CR, Hemmelgarn BR, Paterson JM, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013. doi:10.1136/bmj.f880 DOI  
  19. Navarese EP, Buffon A, Andreotti F, et al. Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus. Am J Cardiol 2013. doi:10.1016/j.amjcard.2012.12.037. DOI  
  20. Cederberg H, Stančáková A, Yaluri N, et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6 year follow-up study of the METSIM cohort. Diabetologia 2015 58:1109-17. PMID: 25754552 PubMed  
  21. Kusters DM, Lahsinoui HH, et al. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther 2012; 10: 363-78. PubMed  
  22. Bakkebø T. Lipidsenkende midler ved graviditet og amming. Utposten 2014; 3: 46-7. PubMed  
  23. Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ 2015; 350: h1035. doi:10.1136/bmj.h1035 DOI  
  • Olav Spigset, overlege, professor dr. med., Avdeling for klinisk farmakologi, St. Olavs Hospital